This model provides detailed sales and volume forecast data for the inflammatory bowel disease market. Including Crohn’s disease and ulcerative colitis market sizing, within the context of total brand sales across the seven major markets.
Reasons to Purchase
*Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
*Understand IBD market trends and assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products
*Access a case study assessing the likelihood of ulcerative colitis approval for Humira and Simponi with three alternative scenario forecasts
#N/A
Other selected research from the 'Gastroenterology' category:
Commercial and Pipeline Perspectives: Lower GI Disorders - Remicade Leads Growth as Novel Biologics Compete for Market Share in Inflammatory Bowel Disease
IBD pipeline products are set to challenge Remicade and other existing therapies in the management of the disease. Competition will intensify as CDP870, Antegren, and Humira provide new alternatives in the severe Crohn`s disease market, and mode of administration will be a key element of product differentiation. In ulcerative colitis, drugs with novel mechanisms will compete for patient share. Learn More
Financial Markets Research: Santarus, Inc.s Zegerid - Fast-acting formulation gaining momentum in GERD
Following the lackluster 2004 launch of an oral suspension formulation of Santarus’ lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus’ future success is tied to the commercial potential for the recently launched Zegerid oral capsule formulation to drive near-term revenues. Learn More